A 49-year-old woman with obesity and type 2 diabetes is found to have mildly elevated alanine aminotransferase and ultrasound evidence of hepatic steatosis. There is no significant alcohol intake and viral hepatitis serology is negative. According to Canadian guidance on metabolic dysfunction-associated steatotic liver disease, what is the cornerstone of initial management?